{"entity":{"id":"nct05405595","kind":"trial","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ADG126, Pembrolizumab, Bevacizumab, Trifluridine/tipiracil and Fruquintinib in advanced solid tumours, run by Adagene Inc, now recruiting.","summary":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05405595 by Adagene Inc, with 186 participants planned, started 2022-06-15 and due to reach its primary completion in 2026-10-31. Interventions recorded: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) and Standard of care (Fruquintinib).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05405595","url":"https://clinicaltrials.gov/study/NCT05405595"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adg126","pembrolizumab","bevacizumab","trifluridine-tipiracil","fruquintinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05405595","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Adagene Inc","participation":[{"nct":"NCT05405595","source":"https://clinicaltrials.gov/study/NCT05405595","fetchedAt":"2026-10-07T16:53:41.920Z","studySha256":"e2880f0c0a8b9e3c91247b9c484ee20d0a6f36f76369ce74d2989c355f680fcd","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-07","leadSponsor":"Adagene Inc","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":186,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":16,"countries":["China","South Korea","United States"]}],"started":"2022-06-15","startedType":"actual","enrolled":186,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05405595/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}